{"id":"W3119279423","doi":"10.1136/ijgc-2020-esgo.223","title":"596 A randomised phase II study of nintedanib (BIBF1120) compared to chemotherapy in patients with recurrent clear cell carcinoma of the ovary or endometrium. (NICCC/ENGOT-OV36)","year":2020,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Nintedanib; Medicine; Internal medicine; Chemotherapy; Topotecan; Clinical endpoint; Oncology; Progression-free survival; Ovarian cancer; Phases of clinical research; Gastroenterology; Urology; Cancer; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001076933,0.001528734,0.00268205,0.00042718,0.0003639315,0.000811035,0.0009669911,0.001769863,0.01271859],"category_scores_gemma":[0.001394483,0.0007164914,0.001691227,0.0004652849,0.0009852893,0.0007386984,0.0003906284,0.002939966,0.002170885],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007122905,"about_ca_system_score_gemma":0.001030372,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001910947,"about_ca_topic_score_gemma":0.003564726,"domain_scores_codex":[0.9994664,0.000320878,0.00003133422,0.00007599478,0.00003057502,0.00007485856],"domain_scores_gemma":[0.999392,0.0001563089,0.000105495,0.00005821207,0.0000324891,0.0002555322],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9834809,0.00307704,0.0002477899,0.0003887387,0.0003724922,0.00002392166,0.00002000831,0.0001730384,0.002208194,0.00006888494,0.0007255692,0.009213474],"study_design_scores_gemma":[0.9585301,0.03971846,0.0007283851,0.00001804745,0.0001626708,0.00001871794,0.000007897329,0.0001316783,0.0001551457,0.00005505608,0.0004658844,0.000007824438],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9756721,0.006674435,0.0007584426,0.001185773,0.001456716,0.005393799,0.003340569,0.0001774654,0.005340737],"genre_scores_gemma":[0.9655108,0.005856032,0.002398668,0.002276426,0.0008612275,0.005750504,0.004667017,0.00006653595,0.01261275],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01271859,"threshold_uncertainty_score":0.04254794,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03735796590788373,"score_gpt":0.3249689820830975,"score_spread":0.2876110161752138,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}